CYBN
CybinCYBN
CYBN
About: Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Employees: 50
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
347% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $268K
40% more capital invested
Capital invested by funds: $49.6M [Q1] → $69.3M (+$19.7M) [Q2]
1.33% less ownership
Funds ownership: 37.22% [Q1] → 35.89% (-1.33%) [Q2]
4% less funds holding
Funds holding: 57 [Q1] → 55 (-2) [Q2]
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$70
835%
upside
Avg. target
$70
835%
upside
High target
$70
835%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Sumant Kulkarni | 835%upside $70 | Buy Maintained | 8 Jul 2025 |
Financial journalist opinion
Based on 5 articles about CYBN published over the past 30 days
Neutral
Business Wire
8 hours ago
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has received approval in Australia to conduct the EMBRACE® study. EMBRACE is the second pivotal study in PARADIGM™, the Company's Phase 3 multinational program evaluating CYB003, a proprietary deuterated psiloci.
Neutral
Business Wire
1 week ago
Cybin Announces Results of Annual Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the “Meeting”). There were 90 shareholders represented in person or by proxy at the.
Neutral
Business Wire
1 week ago
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones. “With our recently announced funding agreement in place, we are well pos.
Neutral
Business Wire
2 weeks ago
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that its Clinical Trial Application (“CTA”) has been approved by the Irish Medicines Board, acting as the reference Member state, to initiate the EMBRACE™ study in Ireland, Poland, and Greece. EMBRACE is the second pivo.
Neutral
Business Wire
2 weeks ago
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference, on August 12, 2025 in Boston, MA. Mr. Drysdale's fireside cha.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High?
The consensus price target hints at an 831.4% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
1 month ago
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has received approval from the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) to commence EMBRACE, the second pivotal study in PARADIGM, the Company's Phase 3 multinational program evaluating CYB0.
Positive
MarketBeat
1 month ago
3 High-Risk, High-Reward Stocks With Explosive Upside
Investors hunting for firms with massive growth potential often look to trending industries, which are primed to benefit from near-term hype and, in many cases, an influx of demand and capital.
Neutral
Business Wire
1 month ago
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with High Trail Special Situations LLC (“High Trail”), pursuant to which the Company agreed to sell a.
Neutral
Business Wire
1 month ago
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported audited financial results for its fiscal year ended March 31, 2025, and recent business highlights. “During the past 12 months, we have continued to focus on building out the strong foundation that underpins.
Charts implemented using Lightweight Charts™